Alzheimer’s disease, a progressively deteriorating neurological disorder, leads to the death of brain cells, ultimately resulting in memory loss, impaired thinking, and difficulty performing even the simplest daily tasks.
A remarkable stride has been made in its treatment with the advent of Donanemab, a drug that has demonstrated promising results in decelerating cognitive decline. Expected to be commercially available by year-end, Donanemab from Eli Lilly generates optimism among medical practitioners, presenting a substantial progression over Leqembi, another well-acclaimed medication in this domain.
However, despite being a significant milestone, these medications’ efficacy has raised questions among experts. Even though both drugs aim to treat Alzheimer’s by targeting amyloid protein deposits in the brain, many emphasize the limited nature of their impact, as expressed in several editorials in the Journal of the American Medical Association.
The Path Forward with Alzheimer’s Treatment
In a comprehensive study involving over 1,700 subjects, Donanemab users exhibited a 35% slower disease progression rate than the placebo group. This equated to a six-point reduction on a 144-point scale, in contrast to the placebo group’s nine-point loss, thus underscoring the need for extended research to assess the drug’s effectiveness and safety.
Despite the surrounding scepticism, the trial’s findings have revealed valuable information. The increasing effectiveness of the drug over time implies potential escalated benefits for Alzheimer’s patients. Additionally, the trial highlighted that earlier treatment, especially in patients exhibiting moderate cognitive impairment, yielded superior results.
Still, the journey ahead holds significant challenges. Administered intravenously, these drugs can potentially induce brain oedema and bleeding. Furthermore, the high costs of these medications pose a concern, with Leqembi priced at $26,500 annually without insurance. Efforts are also required to ensure diversity in clinical trials and enhance health equity.
In conclusion, the authorization of Leqembi and the impending availability of Donanemab mark new chapters in Alzheimer’s treatment. However, further exploration is vital to understand their benefits and address safety and accessibility issues fully. Nevertheless, these drugs offer hope for many battling this challenging disease.
